Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III norursodeoxycholic acid versus placebo in primary sclerosing cholangitis
NL-OMON59345Phase 3Completed
- Sponsor
- Dr. Falk Pharma GmbH
- Start
- Feb 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Primary Sclerosing Cholangitis (PSC) comparing norursodeoxycholic acid with placebo (2 arms). Primary endpoint: Partial normalization of serum alkaline phosphatase and no worsening of disease stage by Ludwig stage. Started Feb 2019; status: completed.
02
Drugs
norursodeoxycholic acid
03
Conditions
Primary Sclerosing Cholangitis (PSC)
Beyond the preview
Go deeper on NL-OMON59345.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59345.